Copanlisib: uses, dosing, side effects & brands
Copanlisib is a medicine sold in the U.S. under one brand. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Powder
- Sold as
- Aliqopa
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
Every copanlisib product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Aliqopa.
Copanlisib and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for copanlisib: levels in milk, effects in breastfed infants, and the drugs it would consider insteadCopanlisib has been removed from the US market. No information is available on the clinical use of copanlisib during breastfeeding. Because copanlisib's half-life is about 39 hours, it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during copanlisib therapy and for 1 month after the last dose.
National Institute of Child Health and Human Development, record revised November 15, 2023. LactMed states its information is not a substitute for professional judgement.
Related calculators
Frequently asked questions
Can you take copanlisib with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run copanlisib against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does copanlisib come in?
Across the brands we track, copanlisib is currently marketed as powder, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic copanlisib?
We do not currently list a generic-labelled copanlisib product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Copanlisib: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/copanlisib
- MLA
- “Copanlisib: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/copanlisib.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for copanlisib on DailyMed (NIH) ↗.